<DOC>
	<DOCNO>NCT00776802</DOCNO>
	<brief_summary>Phase 1/2 , open-label , dose-escalation study assess safety tolerability GCS-100 combination etoposide dexamethasone patient relapse refractory diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>GCS-100LE Combination With Etoposide Dexamethasone Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This study investigate safety efficacy combination GCS-100 etoposide dexamethasone . In vitro data demonstrate potentiation kill lymphoma cell GCS-100 combine dexamethasone etoposide ( Linda Baum , unpublished data ; Finbarr Cotter et al , Annals Oncology , vol 16 , 205 , Suppl 5 . ) GCS-100 administer increase dos define maximum tolerate dose ( MTD ) combination chemotherapeutic agent . When MTD define , cohort expand characterize efficacy combination .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Male female patient 18 year age old diffuse large Bcell cell lymphoma ( DLBCL ) relapse refractory initial therapy : Are candidate autologous stem cell transplant . Have relapse autologous allogeneic stem cell transplant . Have relapse refractory disease 3 successive chemotherapy regimen . ECOG Performance Score 02 Creatinine clearance &gt; 60 mL/min/1.73 m2 . Total bilirubin ≤2.0 X Institutional Upper Limit Normal ( IULN ) AST ( SGOT ) /ALT ( SGPT ) ≤2.5 X IUNL , ≤5X IUNL patient liver involvement DLBCL Absolute neutrophil count &gt; 1,000 /_L ; hemoglobin &gt; 9 g/mL ; platelet count &gt; 75,000 /_L screening . Patients must capable understand purpose risk study able provide write consent . Patients must willing able comply prescribe treatment protocol evaluation Treatment experimental ( unlicensed ) drug within 3 week treatment . Previous chemotherapy , major surgery within 21 day prior first study treatment , radiation therapy within 6 week . Rapidly progressive disease organ function threaten disease Serious , uncontrolled active infection . Serologically positive HIV , HBV , HCV . Clinically significant cardiac , pulmonary , and/or hepatic dysfunction Lymphoma involve central nervous system Female patient pregnant breast feed . Patients capable understanding purpose risk study unable provide write consent . Patients willing unable comply prescribe treatment protocol evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>GCS-100</keyword>
	<keyword>Diffuse Large B-cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Relapsed refractory DLBCL</keyword>
	<keyword>Etoposide ; Dexamethasone</keyword>
</DOC>